{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:39:32Z","timestamp":1777934372985,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>The Food and Drug Administration has recently approved two autologous chimeric antigen receptor T-cell immunotherapies tisagenlecleucel (Kymriah\u2122) and axicabtagene ciloleucel (Yescarta\u2122) for patients with advanced lymphocytic malignancies. Both immunotherapies target the CD19-positive B-cell neoplasms. Kymriah\u2122 is indicated for the treatment of relapsed or refractory acute lymphoblastic leukemia and large B-cell lymphoma. Yescarta\u2122 is indicated for lymphoma only. Although the new therapy offers a promise for patients with advanced disease, it is associated with adverse events including neurotoxicity and cytokine release syndrome, which can be fatal and may require a high level of multidisciplinary supportive care. Due to the risks, both Kymriah\u2122 and Yescarta\u2122 are subject to Risk Evaluation and Mitigation Strategy (REMS) protocols. As active members of multidisciplinary clinical teams, pharmacists are likely to be responsible for the execution of Kymriah\u2122 and Yescarta\u2122 REMS programs. This manuscript describes foundational science and clinical knowledge of chimeric antigen receptor T-cell immunotherapies, common therapy-specific toxicities and REMS requirements for Kymriah\u2122 and Yescarta\u2122 in relation to practice of pharmacy.<\/jats:p>","DOI":"10.1177\/1078155219836480","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T21:25:27Z","timestamp":1553030727000},"page":"1217-1225","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice"],"prefix":"10.1177","volume":"25","author":[{"given":"Anna","family":"Dushenkov","sequence":"first","affiliation":[{"name":"School of Pharmacy & Health Sciences, Fairleigh Dickinson University, Florham Park, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5430-6887","authenticated-orcid":false,"given":"Paiboon","family":"Jungsuwadee","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Health Sciences, Fairleigh Dickinson University, Florham Park, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"bibr1-1078155219836480","unstructured":"Kymriah\u2122 [package insert]. East Hanover, NJ: Novatis Pharmaceutical Corporation, 2018."},{"key":"bibr2-1078155219836480","unstructured":"Yescarta\u2122 [package insert]. Santa Monica, CA: Kite Pharma, Inc., 2018."},{"key":"bibr3-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"bibr4-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"bibr5-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967"},{"key":"bibr6-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"bibr7-1078155219836480","unstructured":"Kymriah\u2122 risk evaluation and mitigation strategy (REMS). East Hanover, NJ: Novatis Pharmaceutical Corporation, 2018."},{"key":"bibr8-1078155219836480","unstructured":"Yescarta\u2122 Risk evaluation and mitigation strategy (REMS). Santa Monica, CA: Kite Pharma, Inc., 2018."},{"key":"bibr9-1078155219836480","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00197"},{"key":"bibr10-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"bibr11-1078155219836480","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.4049\/jimmunol.1301769","volume":"193","author":"Oren R","year":"2014","journal-title":"J Immunol"},{"key":"bibr12-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12136"},{"key":"bibr13-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242606"},{"key":"bibr14-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.16.5879"},{"key":"bibr15-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/980250"},{"key":"bibr16-1078155219836480","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","volume":"4","author":"Chmielewski M","year":"2013","journal-title":"Front Immunol"},{"key":"bibr17-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-128843"},{"key":"bibr18-1078155219836480","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.2014.57.5472","volume":"33","author":"Park JH","year":"2015","journal-title":"J Clin Oncol"},{"key":"bibr19-1078155219836480","doi-asserted-by":"crossref","unstructured":"Maher J, Brentjens RJ, Gunset G, et\u00a0al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor.\n                      Nat Biotechnol\n                      2002; 20: 70\u201375.","DOI":"10.1038\/nbt0102-70"},{"key":"bibr20-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"bibr21-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.210"},{"key":"bibr22-1078155219836480","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","volume":"21","author":"Maus MV","year":"2016","journal-title":"Oncologist"},{"key":"bibr23-1078155219836480","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","volume":"15","author":"Teachey DT","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"bibr24-1078155219836480","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2147\/TCRM.S145039","volume":"14","author":"Jain MD","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"bibr25-1078155219836480","first-page":"577","volume":"130","author":"Schuster SJ","year":"2017","journal-title":"Blood"},{"key":"bibr26-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"bibr27-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"bibr28-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"bibr29-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"bibr30-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"bibr31-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"bibr32-1078155219836480","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hon.2481","volume":"36","author":"Ureshino H","year":"2018","journal-title":"Hematol Oncol"},{"key":"bibr33-1078155219836480","doi-asserted-by":"publisher","DOI":"10.3109\/08830189809042997"},{"key":"bibr34-1078155219836480","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.7150\/ijbs.4666","volume":"8","author":"Tanaka T","year":"2012","journal-title":"Int J Biol Sci"},{"key":"bibr35-1078155219836480","unstructured":"Actemra\u00ae [package insert]. South San Francisco, CA: Genentech, Inc., 2018."},{"key":"bibr36-1078155219836480","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"bibr37-1078155219836480","unstructured":"Lexicomp Online, Lexi-Drugs Online. Lexi-Comp, Inc., 2018."},{"key":"bibr38-1078155219836480","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","volume":"15","author":"Neelapu SS","year":"2018","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219836480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219836480","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219836480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:20:57Z","timestamp":1777688457000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219836480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1177\/1078155219836480"],"URL":"https:\/\/doi.org\/10.1177\/1078155219836480","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]}}}